Novartis CEO says it is watching US reciprocal tariff policy 'very carefully'
Portfolio Pulse from
Novartis is closely monitoring the potential impact of the US's proposed reciprocal tariff policy, which could impose a 25% import duty on pharmaceuticals. This move is part of broader trade measures by the US government.
March 17, 2025 | 6:00 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Novartis is monitoring the US's proposed 25% import duty on pharmaceuticals, which could impact its business operations and costs.
The proposed 25% import duty on pharmaceuticals by the US could increase costs for Novartis, affecting its profitability and operations. As a major player in the pharmaceutical industry, any changes in trade policy could have significant implications for the company.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80